0413 GMT - Public market sentiment toward Monash IVF could take a long while to improve following the fertility services provider's embryo mix-up at its Brisbane clinic, Jefferies analysts tell clients. Last week, Monash's shares tumbled 36% in a day on news that an embryo was transferred to the wrong patient, resulting in the birth of a child. Warning that sentiment toward Monash to remain weak for some time, the Jefferies analysts mull recent private-equity activity in the IVF space. They tell clients in a note that the historic transaction multiple for IVF assets is 13.8 times Ebitda for the last 12 months. Jefferies keeps a buy rating and A$1.45 target price on the stock, which is up 3.3% at A$0.7125. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 00:13 ET (04:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.